BCPC Pengajuan SEC - Balchem Corporation- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300VR70OPMHUI3557
CIK	9326

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Balchem Corporation

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

July 31, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Corp
July 31, 2025	EX-99.1	Balchem Corporation Reports Second Quarter 2025 Financial Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Second Quarter 2025 Financial Results Montvale, NJ, July 31, 2025 - Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 mill
July 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 31, 2025 Balchem Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 31, 2025 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 24, 2025	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 [ ] TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the addre
June 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 18, 2025 Balchem Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 18, 2025 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
April 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
April 24, 2025	EX-99.1	Balchem Corporation Reports First Quarter 2025 Financial Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports First Quarter 2025 Financial Results Montvale, NJ, April 24, 2025 - Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 mill
April 24, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 24, 2025 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File N
April 24, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Cor
April 24, 2025	EX-10.3	Form of Agreement, Balchem Corporation Performance Share Unit Grant Agreement (filed herewith).* EXHIBIT 10.3 FORM OF AGREEMENT (AS OF MARCH 2025) BALCHEM CORPORATION PERFORMANCE SHARE UNIT GRANT AGREEMENT 2017 Omnibus Incentive Plan This PERFORMANCE SHARE UNIT GRANT AGREEMENT (the “Agreement”) made as of this th day of , is between Balchem Corporation, a Maryland corporation (the “Company”) and (“Grantee”). 1.Grant of PSUs. Pursuant to the Company’s 2017 Omnibus Incentive Plan, as the same m
April 24, 2025	EX-10.4	Form of Agreement, Balchem Corporation Non-Employee Director Restricted Stock Grant Agreement (filed herewith).* EXHIBIT 10.4 FORM OF AGREEMENT (AS OF MARCH 2025) BALCHEM CORPORATION NON-EMPLOYEE DIRECTORS RESTRICTED STOCK GRANT AGREEMENT 2017 Omnibus Incentive Plan RESTRICTED STOCK GRANT AGREEMENT (this “Agreement”) is made as of this th day of , , between Balchem Corporation, a Maryland corporation (the “Company”) and (“Grantee”). 1. Grant of Restricted Stock. Pursuant to the Company’s 2017 Omnibus Incenti
April 24, 2025	EX-10.2	Form of Agreement, Balchem Corporation Restricted Stock Grant Agreement (filed herewith).* EXHIBIT 10.2 FORM OF AGREEMENT (AS OF MARCH 2025) BALCHEM CORPORATION RESTRICTED STOCK GRANT AGREEMENT 2017 Omnibus Incentive Plan This RESTRICTED STOCK GRANT AGREEMENT (the “Agreement”), is made as of this th day of , , between Balchem Corporation, a Maryland corporation (the “Company”) and (“Grantee”). 1. Grant of Restricted Stock. Pursuant to the Company’s 2017 Omnibus Incentive Plan, as the sa
March 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Balchem Corpora UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 21, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
February 21, 2025	EX-19.1	Balchem Corporation Insider Trading Policy (filed herewith). Exhibit 19.1 BALCHEM CORPORATION INSIDER TRADING POLICY I. PURPOSE This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Balchem Corporation (“Balchem” or the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Directors has adopted this Po
February 21, 2025	EX-10.15	Balchem Deferred Compensation Plan (filed herewith).* Exhibit 10.15 BALCHEM DEFERRED COMPENSATION PLAN Balchem Corporation, a Maryland corporation (the "Company"), hereby establishes the Balchem Deferred Compensation Plan (the "Plan"), effective June 1, 2018 (the "Effective Date"), for the purpose of attracting and retaining high quality executives, and promoting in them increased efficiency and an interest in the successful operation of the Company.
February 21, 2025	EX-4.1	Description of Securities (filed herewith). Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Balchem Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.06-2/3 per
February 21, 2025	EX-21.1	Subsidiaries of Registrant (filed herewith). Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization Aberco, Inc. Maryland Albion Laboratories, Inc. Nevada Balchem BV Netherlands Balchem Canada Corporation Canada Balchem Italia Srl Italy Balchem Ltd. Canada Balchem NV Belgium Balchem Philippines, Inc. Philippines Balchem Pty Ltd. Australia Balchem Sdn Bhd Malaysia BCP Ingredients, Inc. Delaware Kappa Bio
February 21, 2025	EX-99.1	Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results Montvale, NJ, February 21, 2025 - Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net
February 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 21, 2025 Balchem Corpora UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 21, 2025 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 21, 2025	EX-10.14	Theodore L. Harris Stock Option Grant Agreement, Exhibit 10.14 BALCHEM CORPORATION STOCK OPTION GRANT AGREEMENT 2017 Omnibus Incentive Plan This STOCK OPTION GRANT AGREEMENT (the “Grant”), dated as of September 15, 2022 and amended as of December 9, 2024, is between BALCHEM CORPORATION, a Maryland corporation (the “Company”) and Theodore L. Harris (“Optionee”). W I T N E S S E T H: 1.Grant of Options. Pursuant to the provisions of the Company’s
February 14, 2025	EX-10.1	Balchem Corporation Executive Severance Policy (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 14, 2025).* Exhibit 10.1 BALCHEM CORPORATION EXECUTIVE SEVERANCE POLICY Balchem Corporation, a Maryland corporation (together with its successors and assigns, the “Company”), has adopted this Executive Severance Policy (the “Policy”) effective as of February 12, 2025. Capitalized terms are defined in Section 2 of this Policy; capitalized terms used but not otherwise defined herein shall have the meanings ascr
February 14, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 13, 2025	EX-1	JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $.
December 10, 2024	EX-99.1	Balchem Corporation Announces Dividend Exhibit 99.1 FOR IMMEDIATE RELEASE Balchem Corporation Announces Dividend Montvale, New Jersey. December 10, 2024. Balchem Corporation (NASDAQ: BCPC) today announced that on December 9, 2024, its Board of Directors declared a dividend on its shares of common stock equal to $0.87 per share on the Company’s issued and outstanding Common Stock, to be payable on January 17, 2025 to stockholders of rec
December 10, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
October 25, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
October 25, 2024	EX-99.1	Balchem Corporation Reports Third Quarter 2024 Financial Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Third Quarter 2024 Financial Results Montvale, NJ, October 25, 2024 - Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal third quarter ended September 30, 2024. For the quarter, the Company reported net sales of $239.9 million, net earnings of $33.
October 25, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 25, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
October 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
September 20, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fi
September 20, 2024	EX-3.1	Balchem Corporation Articles Supplementary (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on September 20, 2024). Exhibit 3.1 BALCHEM CORPORATION ARTICLES SUPPLEMENTARY Balchem Corporation, a Maryland corporation (the “Company”), hereby certifies to the State Department of Assessments and Taxation of Maryland (the “SDAT”) that: FIRST: Under a power contained in Title 3, Subtitle 8 of the Maryland General Corporation Law (the “MGCL”), by resolution duly adopted by the Board of Directors of the Company (the “Bo
July 26, 2024	EX-99.1	Balchem Corporation Reports Second Quarter 2024 Financial Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Second Quarter 2024 Financial Results Montvale, NJ, July 26, 2024 - Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal second quarter ended June 30, 2024. The Company reported quarterly net sales of $234.1 million, quarterly net earnings of $32.1 m
July 26, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Corp
July 26, 2024	EX-10.1	Form of Balchem Corporation Non-Employee Directors Restricted Stock Grant Agreement (filed herewith).* EXHIBIT 10.1 BALCHEM CORPORATION NON-EMPLOYEE DIRECTORS RESTRICTED STOCK GRANT AGREEMENT 2017 Omnibus Incentive Plan RESTRICTED STOCK GRANT AGREEMENT (this “Agreement”) is made as of this th day of , , between Balchem Corporation, a Maryland corporation (the “Company”) and (“Grantee”). 1. Grant of Restricted Stock. Pursuant to the Company’s 2017 Omnibus Incentive Plan, as the same may be amended f
July 26, 2024	EX-10.2	Form of Balchem Corporation Stock Option Grant Agreement Non-Employee Director (filed herewith).* EXHIBIT 10.2 BALCHEM CORPORATION STOCK OPTION GRANT AGREEMENT NON-EMPLOYEE DIRECTOR 2017 Omnibus Incentive Plan This STOCK OPTION GRANT AGREEMENT (the “Grant”), dated as of is between BALCHEM CORPORATION, a Maryland corporation (the “Company”) and (“Optionee”). W I T N E S S E T H: 1. Grant of Options. Pursuant to the provisions of the Company’s 2017 Omnibus Incentive Plan, as the same may be amen
July 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 26, 2024 Balchem Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 26, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 24, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 20, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 18, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 [ ] TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the addre
May 3, 2024	EX-99.1	Balchem Corporation Reports First Quarter 2024 Financial Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports First Quarter 2024 Financial Results Montvale, NJ, May 3, 2024 - Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal first quarter ended March 31, 2024. The Company reported quarterly net sales of $239.7 million, quarterly net earnings of $29.0 mill
May 3, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Cor
May 3, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 3, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Numb
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
March 29, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File N
February 16, 2024	EX-97.1	Balchem Corporation Incentive-Based Compensation Recovery Policy (filed herewith).* Exhibit 97.1 BALCHEM CORPORATION INCENTIVE-BASED COMPENSATION RECOVERY POLICY PURPOSE The Board of Directors (the “Board”) of Balchem Corporation (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The
February 16, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 16, 2024 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 16, 2024	EX-10.7	Form of Agreement, Balchem Corporation Restricted Stock Grant Agreement (filed herewith).* FORM OF AGREEMENT (AS OF FEBRUARY 2024) Exhibit 10.7 BALCHEM CORPORATION RESTRICTED STOCK GRANT AGREEMENT 2017 Omnibus Incentive Plan This RESTRICTED STOCK GRANT AGREEMENT (the “Agreement”), is made as of this th day of , , between Balchem Corporation, a Maryland corporation (the “Company”) and (“Grantee”). 1. Grant of Restricted Stock. Pursuant to the Company’s 2017 Omnibus Incentive Plan, as the
February 16, 2024	EX-4.1	Description of Securities (filed herewith). Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Balchem Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.06-2/3 per
February 16, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
February 16, 2024	EX-10.8	Form of Agreement, Balchem Corporation Performance Share Unit Grant Agreement ( FORM OF AGREEMENT (AS OF FEBRUARY 2024) Exhibit 10.8 BALCHEM CORPORATION PERFORMANCE SHARE UNIT GRANT AGREEMENT 2017 Omnibus Incentive Plan This PERFORMANCE SHARE UNIT GRANT AGREEMENT (the “Agreement”) made as of this th day of , is between Balchem Corporation, a Maryland corporation (the “Company”) and (“Grantee”). 1.Grant of PSUs. Pursuant to the Company’s 2017 Omnibus Incentive Plan, as the sam
February 16, 2024	EX-10.9	Form of Agreement, Balchem Corporation Stock Option FORM OF AGREEMENT (AS OF FEBRUARY 2024) Exhibit 10.9 BALCHEM CORPORATION STOCK OPTION GRANT AGREEMENT 2017 Omnibus Incentive Plan This STOCK OPTION GRANT AGREEMENT (the “Grant”), dated as of , is between BALCHEM CORPORATION, a Maryland corporation (the “Company”) and (“Optionee”). W I T N E S S E T H: 1.Grant of Options. Pursuant to the provisions of the Company’s 2017 Omnibus Incentive Plan, as t
February 16, 2024	EX-99.1	Balchem Corporation Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Fourth Quarter and Full Year 2023 Financial Results Montvale, NJ, February 16, 2024 - Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2023 fiscal fourth quarter ended December 31, 2023. The Company reported quarterly net sales of $228.7 million, quarterly n
February 16, 2024	EX-21.1	Subsidiaries of Registrant (filed herewith). Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization Aberco, Inc. Maryland Albion Laboratories, Inc. Nevada Balchem BV Netherlands Balchem Italia Srl Italy Balchem Ltd. Canada Balchem NV Belgium Balchem Pty Ltd. Australia Balchem Sdn Bhd Malaysia BCP Ingredients, Inc. Delaware Kappa Bioscience AS Norway Kappa Bioscience Europe GmbH Germany Kappa Solutions A
February 16, 2024	EX-10.10	Balchem Corporation Officer Retiree Program ( Exhibit 10.10 Balchem Corporation Officer Retiree Program Balchem Corporation (the “Company”) sets forth the below Officer Retiree Program (the “Program”) with the intent to help attract and retain top talent at the executive level. For purposes of this Program, the term "Retirement" shall mean voluntary termination of employment at a time when the sum of the Officer’s age and years of service is
February 13, 2024	SC 13G/A	BCPC / Balchem Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0397-balchemcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Balchem Corp Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule
February 7, 2024	EX-1	Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, with $0.06 2/3 par value of Balchem Corp., beneficially owned by them, together with any or all amendments thereto, when and if appropriate.
February 7, 2024	SC 13G/A	BCPC / Balchem Corporation / APG Asset Management US Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
December 5, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
December 5, 2023	EX-99.1	Balchem Corporation Announces Dividend Exhibit 99.1 FOR IMMEDIATE RELEASE Balchem Corporation Announces Dividend Montvale, New Jersey. December 5, 2023. Balchem Corporation (NASDAQ: BCPC) today announced that on December 4, 2023, its Board of Directors declared a dividend on its shares of common stock equal to $0.79 per share on the Company’s issued and outstanding Common Stock, to be payable on January 19, 2024 to stockholders of reco
October 27, 2023	EX-99.1	Balchem Corporation Reports Third Quarter Sales of $229.9 Million, with Net Earnings of $29.1 Million, GAAP EPS of $0.90, and Adjusted EPS of $1.04 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Third Quarter Sales of $229.9 Million, with Net Earnings of $29.1 Million, GAAP EPS of $0.90, and Adjusted EPS of $1.04 Montvale, NJ, October 27, 2023 - Balchem Corporation (NASDAQ: BCPC) reported today third quarter net sales of $229.9 million for 2023, compared to net sales of $244.
October 27, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 27, 2023 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
October 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
September 5, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
July 28, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 28, 2023 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
July 28, 2023	EX-99.1	Balchem Corporation Reports Second Quarter Sales of $231.3 Million, with Net Earnings of $30.1 Million, GAAP EPS of $0.93, and Adjusted EPS of $1.06 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Second Quarter Sales of $231.3 Million, with Net Earnings of $30.1 Million, GAAP EPS of $0.93, and Adjusted EPS of $1.06 Montvale, NJ, July 28, 2023 - Balchem Corporation (NASDAQ: BCPC) reported today second quarter net sales of $231.3 million for 2023, compared to net sales of $236.7
July 28, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Corp
June 29, 2023	EX-FILING FEES	Calculation of Filing Fee Table FORM S-8 (Form Type) Balchem Corporation (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Balchem Corporation (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $.
June 29, 2023	S-8	As filed with the Securities and Exchange Commission on June 28, 2023 As filed with the Securities and Exchange Commission on June 28, 2023 Registration No.
June 26, 2023	EX-10.1	Amended and Restated Balchem Corporation 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed on June 26, 2023).* Exhibit 10.1 BALCHEM CORPORATION 2017 OMNIBUS INCENTIVE PLAN (AS AMENDED AND RESTATED AS OF JUNE 22, 2023) 1. Purpose. The purpose of this 2017 Omnibus Incentive Plan (the “Plan”) is to aid Balchem Corporation, a Maryland corporation (together with its successors and assigns, the “Company”), in attracting, retaining, motivating and rewarding employees, non-employee directors and consultants of the
June 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 22, 2023 Balchem Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 22, 2023 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 20, 2023	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 [ ] TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the addre
June 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 28, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Cor
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 ny20005644x2def14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
April 28, 2023	EX-99.1	Balchem Corporation Reports Record First Quarter Sales of $232.5 Million, with Net Earnings of $22.7 Million, GAAP EPS of $0.70, and Adjusted EPS of $0.94 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record First Quarter Sales of $232.5 Million, with Net Earnings of $22.7 Million, GAAP EPS of $0.70, and Adjusted EPS of $0.94 Montvale, NJ, April 28, 2023 - Balchem Corporation (NASDAQ: BCPC) reported today first quarter net sales of $232.5 million for 2023, compared to net sales of
April 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 28, 2023 Balchem Corporatio UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 28, 2023 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File N
February 24, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
February 24, 2023	EX-4.1	Description of Securitie Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Balchem Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.06-2/3 per share (“common stock”). References herein to “we,” “us,”
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 24, 2023 Balchem Corpora UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 24, 2023 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 24, 2023	EX-99.1	Balchem Corporation Reports Fourth Quarter Net Sales Growth of 9.1% and Strong Full Year 2022 Results Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Fourth Quarter Net Sales Growth of 9.1% and Strong Full Year 2022 Results Montvale, NJ, February 24, 2023 - Balchem Corporation (NASDAQ: BCPC) reported today fourth quarter net sales of $232.5 million for 2022, compared to net sales of $213.1 million for the fourth quarter 2021. Fourt
February 24, 2023	EX-10.8	Balchem Corporation Director Retiree Program (incorporated by reference to Exhibit 10.8 to the Company's Annual Report on Form 10-K filed on February 24, 2023).* Exhibit 10.8 Balchem Corporation Director Retiree Program For purposes of the Director Retiree Program, the term “Retirement” shall mean: i.voluntary retirement from the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) at the conclusion of his or her term in which he or she reaches the age of 70 in accordance with the Company’s Corporate Governance Guidelines; and the combin
February 24, 2023	EX-10.7	Balchem Corporation Officer Retiree Program (filed herewith) Exhibit 10.7 Balchem Corporation Officer Retiree Program For purposes of the Officer Retiree Program, the term "Retirement" shall mean voluntary termination of employment at a time when the sum of the Officer’s age and years of service is at least 70, provided that officer has at least ten years of service and has served three consecutive years as an Officer. A requirement of eligibility for this
February 24, 2023	EX-10.1	Balchem Corporation 401(k) Basic Plan Document #01, as amended by the Balchem Corporation 401(K) Plan Amendment of January 1, 2023 (incorporated by reference to Exhibit 10.1 to the Company's Annual Report on Form 10-K filed on February 24, 2023).* Exhibit 10.1 BASIC PLAN DOCUMENT #01 Copyright © 2002-2022 Empower Retirement, LLC All Rights Reserved. EMPOWER RETIREMENT, LLC TABLE OF CONTENTS ARTICLE 1 INTRODUCTION 1 Section 1.01 Plan 1 Section 1.02 Application of Plan 1 ARTICLE 2 DEFINITIONS 2 ARTICLE 3 PARTICIPATION 18 Section 3.01 Elective Deferrals and Voluntary Contributions 18 Section 3.02 Matching Contributions 18 Section 3.03 Employer
February 24, 2023	EX-21.1	Subsidiaries of Registrant Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization Aberco, Inc. Maryland Albion Laboratories, Inc. Nevada Balchem BV Netherlands Balchem Italia Srl Italy Balchem Ltd. Canada Balchem NV Belgium Balchem Pty Ltd. Australia Balchem Sdn Bhd Malaysia BCP Ingredients, Inc. Delaware Biogenic Innovations, LLC Washington Cardinal Associates, Inc. Washington Kappa B
February 9, 2023	SC 13G/A	BCPC / Balchem Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0371-balchemcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Balchem Corp. Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule
January 12, 2023	SC 13G/A	BCPC / Balchem Corporation / APG Asset Management US Inc. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Balchem Corporation (Name of Issuer) Common Stock, $0.06 2/3 par value (Title of Class of Securities) 057665200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
December 7, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
December 7, 2022	EX-3.1	By-laws of the Company, as amended and restated as of Exhibit 3.1 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF DECEMBER 5, 2022 ARTICLE I OFFICES Section 1. PRINCIPAL OFFICE. The principal office of the Corporation shall be located at such place within or without the state of Maryland as the Board of Directors may from time to time determine or the business of the Corporation may require. The registered agent for the Corporation shall be
December 6, 2022	EX-99.1	Balchem Corporation Announces Dividend Exhibit 99.1 FOR IMMEDIATE RELEASE Balchem Corporation Announces Dividend Montvale, New Jersey, December 6, 2022. Balchem Corporation (NASDAQ: BCPC) today announced that on December 5, 2022, its Board of Directors declared a dividend on its shares of common stock equal to $0.71 per share on the Company?s issued and outstanding Common Stock, to be payable on January 20, 2023 to stockholders of reco
December 6, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
November 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 4, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
November 4, 2022	EX-99.1	Balchem Corporation Reports Third Quarter Sales of $244.3 Million, Net Earnings of $25.2 Million, GAAP EPS of $0.78, and Adjusted EPS of $1.00 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Third Quarter Sales of $244.3 Million, Net Earnings of $25.2 Million, GAAP EPS of $0.78, and Adjusted EPS of $1.00 Montvale, NJ, November 4, 2022 - Balchem Corporation (NASDAQ: BCPC) reported today third quarter net earnings of $25.2 million for 2022, compared to net earnings of $25.0
November 4, 2022	EX-10.1	Theodore L. Harris Stock Option Grant Agreement, dated September 15, 2022 Exhibit 10.1 BALCHEM CORPORATION STOCK OPTION GRANT AGREEMENT 2017 Omnibus Incentive Plan This STOCK OPTION GRANT AGREEMENT (the ?Grant?), dated as of September 15, 2022 is between BALCHEM CORPORATION, a Maryland corporation (the ?Company?) and Theodore L. Harris (?Optionee?). W I T N E S S E T H: 1.Grant of Options. Pursuant to the provisions of the Company?s 2017 Omnibus Incentive Plan, as the s
September 29, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fi
September 20, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fi
September 20, 2022	EX-3.1	EX-3.1 Exhibit 3.1 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF SEPTEMBER 15, 2022 ARTICLE I OFFICES Section 1. PRINCIPAL OFFICE. The principal office of the Corporation shall be located at such place within or without the state of Maryland as the Board of Directors may from time to time determine or the business of the Corporation may require. The registered agent for the Corporation shall
September 6, 2022	EX-99.3	Balchem Corporation UNAUDITED PRO FORMA FINANCIAL INFORMATION Exhibit 99.3 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation UNAUDITED PRO FORMA FINANCIAL INFORMATION On June 21, 2022, Balchem and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the huma
September 6, 2022	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 21, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (
September 6, 2022	EX-99.2	Table of Contents Exhibit 99.2 Kechu Bidco Group Consolidated Annual Financial Statements 2021 Kechu Bidco Group Consolidated financial statements 2021 Table of Contents Independent Auditor's Report 3 Consolidated statement of comprehensive income 5 Consolidated statement of financial position 6 Consolidated statement of changes in equity 8 Consolidated statement of cash flows 9 Notes to the consolidated financial
August 30, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
August 30, 2022	EX-99.1	Balchem Corporation acquires Bergstrom Nutrition Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation acquires Bergstrom Nutrition New Hampton, New York, August 30, 2022. Balchem Corporation (NASDAQ:BCPC), a global specialty ingredients company focused on Nutrition and Health, today announced the acquisition of Cardinal Associates Inc., operating as ?Bergstrom Nutrition,? a leading science-ba
August 1, 2022	EX-4.2	Security and Pledge Agreement dated July 27, 2022 among Balchem Corporation, the Obligors, and JPMorgan Chase Bank, N.A., (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on August 1, 2022). Exhibit 4.2 EXECUTION VERSION AMENDED AND RESTATED SECURITY AND PLEDGE AGREEMENT THIS AMENDED AND RESTATED SECURITY AND PLEDGE AGREEMENT (this ?Agreement?) is entered into as of July 27, 2022 among BALCHEM CORPORATION, a Maryland corporation (the ?Parent?), the other parties identified as ?Obligors? on the signature pages hereto and such other parties that may become Obligors hereunder after the d
August 1, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
August 1, 2022	EX-4.1	Amended and Restated Credit Agreement dated July 27, 2022 (the "Amended Credit Agreement") among Balchem Corporation, the Domestic Guarantors (as defined in the Amended Credit Agreement), JPMorgan Chase Bank, N.A., as administrative agent, and the Lenders (as defined in the Amended Credit Agreement) (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on August 1, 2022). Exhibit 4.1 EXECUTION COPY AMENDED AND RESTATED CREDIT AGREEMENT Dated as of July 27, 2022 among BALCHEM CORPORATION, as the Parent, THE FOREIGN SUBSIDIARIES OF THE PARENT IDENTIFIED HEREIN, as the Foreign Borrowers, THE SUBSIDIARIES OF THE PARENT IDENTIFIED HEREIN, as the Guarantors, JPMORGAN CHASE BANK, N.A., as Administrative Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, FARM CREDIT SERVICES O
July 29, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 29, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
July 29, 2022	EX-99.1	Balchem Corporation Reports Second Quarter Sales of $236.7 Million, Net Earnings of $29.8 Million, GAAP EPS of $0.92, and Adjusted EPS of $1.07 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Second Quarter Sales of $236.7 Million, Net Earnings of $29.8 Million, GAAP EPS of $0.92, and Adjusted EPS of $1.07 New Hampton, NY, July 29, 2022 - Balchem Corporation (NASDAQ: BCPC) reported today second quarter net earnings of $29.8 million for 2022, compared to net earnings of $22
July 29, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Corp
June 27, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 21, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 27, 2022	EX-99.1	Balchem Corporation Completes Acquisition of Kappa Bioscience AS Exhibit 99.1 Balchem Corporation Completes Acquisition of Kappa Bioscience AS New Hampton, New York, (June 21, 2022) - Balchem Corporation (NASDAQ:BCPC), a global specialty ingredients company focused on Nutrition and Health, today announced that it completed its acquisition of Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headq
June 22, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the addre
June 15, 2022	EX-99.1	Balchem Corporation Signs Definitive Agreement to Acquire Kappa Bioscience AS Exhibit 99.1 Balchem Corporation Signs Definitive Agreement to Acquire Kappa Bioscience AS New Hampton, New York, (June 14, 2022) - Balchem Corporation (NASDAQ:BCPC), a global specialty ingredients company focused on Nutrition and Health, has signed a definitive agreement to acquire Kappa Bioscience AS (?Kappa?), a leading science-based manufacturer of specialty vitamin K2 for the human nutrition
June 15, 2022	EX-2.1	Share Purchase Agreement between Kechu MidCo AS as the Seller and Balchem Corporation and Balchem B.V. as the Buyers regarding the sale and purchase of the shares in Kechu BidCo AS (incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K filed on June 15, 2022) Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (A) NOT MATERIAL AND (B) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED Share Purchase Agreement between Kechu MidCo AS as the Seller and Balchem Corporation and Balchem B.V. as the Buyers regarding the sale and purchase of the shares in Kechu BidCo AS Dated 13 June 2022 TABLE OF CONTENTS 1 DEFI
June 15, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 13, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 7, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Num
April 29, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Cor
April 29, 2022	EX-99.1	Balchem Corporation Reports First Quarter Sales of $228.9 Million, Net Earnings of $28.9 Million, GAAP EPS of $0.89, and Adjusted EPS of $1.03 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports First Quarter Sales of $228.9 Million, Net Earnings of $28.9 Million, GAAP EPS of $0.89, and Adjusted EPS of $1.03 New Hampton, NY, April 29, 2022 - Balchem Corporation (NASDAQ: BCPC) reported today first quarter net earnings of $28.9 million for 2022, compared to net earnings of $23.
April 29, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 29, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File N
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 ny20001554x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
February 24, 2022	EX-21	Subsidiaries of Registrant. Exhibit 21 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization BCP Ingredients, Inc.
February 24, 2022	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Balchem Corporation had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): its common stock, par value $0.06-2/3 per share (?common stock?). References herein to ?we,? ?us,?
February 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
February 18, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 18, 2022 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 18, 2022	EX-99.1	Balchem Corporation Reports Record Fourth Quarter Sales of $213.1 Million and Net Earnings of $24.9 Million, GAAP EPS of $0.76 and Adjusted EPS of $0.85 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record Fourth Quarter Sales of $213.1 Million and Net Earnings of $24.9 Million, GAAP EPS of $0.76 and Adjusted EPS of $0.85 New Hampton, NY, February 18, 2022 - Balchem Corporation (NASDAQ: BCPC) reported today fourth quarter net earnings of $24.9 million for 2021, compared to net ea
February 9, 2022	SC 13G/A	BCPC / Balchem Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Balchem Corp. Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule
February 4, 2022	EX-99.1	JOINT FILING AGREEMENT CUSIP No 057665200 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
February 4, 2022	SC 13G	BCPC / Balchem Corporation / APG Asset Management US Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Balchem Corporation (Name of Issuer) Common Stock, $0.06 2/3 par value (Title of Class of Securities) 057665200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
December 16, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 15, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
December 16, 2021	EX-99.1	Balchem Corporation Announces Dividend Exhibit 99.1 FOR IMMEDIATE RELEASE Balchem Corporation Announces Dividend New Hampton, New York. December 16, 2021. Balchem Corporation (NASDAQ: BCPC) today announced that on December 15, 2021, its Board of Directors declared a dividend on its shares of common stock equal to $0.64 per share on the Company?s issued and outstanding Common Stock, to be payable on January 21, 2022 to stockholders of r
October 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
October 29, 2021	EX-99.1	Balchem Corporation Reports Record Third Quarter Sales of $197.9 Million, Net Earnings of $25.0 Million, GAAP EPS of $0.77, and Adjusted EPS of $0.92 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record Third Quarter Sales of $197.9 Million, Net Earnings of $25.0 Million, GAAP EPS of $0.77, and Adjusted EPS of $0.92 New Hampton, NY, October 29, 2021 - Balchem Corporation (NASDAQ: BCPC) reported today record third quarter net earnings of $25.0 million for 2021, compared to net
October 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 29, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
July 30, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Corp
July 30, 2021	EX-99.1	Balchem Corporation Reports Record Second Quarter Sales of $202.4 Million, Net Earnings of $22.7 Million, GAAP EPS of $0.70, and Adjusted EPS of $0.93 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record Second Quarter Sales of $202.4 Million, Net Earnings of $22.7 Million, GAAP EPS of $0.70, and Adjusted EPS of $0.93 New Hampton, NY, July 30, 2021 - Balchem Corporation (NASDAQ: BCPC) reported today record second quarter net earnings of $22.7 million for 2021, compared to net e
July 30, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 30, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 21, 2021	EX-3.4	By-laws of the Company, as amended and restated as of June 17, 2021 (incorporated by reference to Exhibit 3.4 to the Company's Current Exhibit 3.4 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF JUNE 17, 2021 ARTICLE I OFFICES Section 1. AGENT FOR THE SERVICE OF PROCESS. The agent for the service of process in the State of Maryland shall be CSC Lawyers Incorporating Service Company, 7th St. Paul St., Suite 820, Baltimore, MD 21202. Section 2. OTHER OFFICES. The Corporation may have offices at such other places within or
June 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 17, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 16, 2021	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the addre
June 4, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 3, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Num
June 4, 2021	EX-3.2	EX-3.2 EX-3.2 2 brhc10025482ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF JUNE 3, 2021 ARTICLE I OFFICES Section 1. AGENT FOR THE SERVICE OF PROCESS. The agent for the service of process in the State of Maryland shall be CSC Lawyers Incorporating Service Company, 7th St. Paul St., Suite 820, Baltimore, MD 21202. Section 2. OTHER OFFICES. The Corporation may h
April 30, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Cor
April 30, 2021	EX-99.1	Balchem Corporation Reports Record First Quarter Sales of $185.7 Million, Net Earnings of $23.4 Million, GAAP EPS of $0.72, and Adjusted EPS of $0.87 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record First Quarter Sales of $185.7 Million, Net Earnings of $23.4 Million, GAAP EPS of $0.72, and Adjusted EPS of $0.87 New Hampton, NY, April 30, 2021 - Balchem Corporation (NASDAQ: BCPC) reported today first quarter 2021 net earnings of $23.4 million, compared to net earnings of $
April 30, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 30, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File N
April 26, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
April 26, 2021	DEF 14A	- DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ?) Filed by the Registrant?? Filed by a Party other than the Registrant?? Check the appropriate box: ??Preliminary Proxy Statement ??Confidential, for Use of the Commission Only (as permitted by Rule 1
February 19, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
February 19, 2021	EX-99.1	Balchem Corporation Reports Record Fourth Quarter Sales of $180.7 Million and Net Earnings of $22.2 Million, GAAP EPS of $0.68 and Adjusted EPS of $0.83 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record Fourth Quarter Sales of $180.7 Million and Net Earnings of $22.2 Million, GAAP EPS of $0.68 and Adjusted EPS of $0.83 New Hampton, NY, February 19, 2021 - Balchem Corporation (NASDAQ: BCPC) reported today fourth quarter net earnings of $22.2 million for 2020, compared to net ea
February 19, 2021	EX-21	Subsidiaries of Registrant. Exhibit 21 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization BCP Ingredients, Inc.
February 19, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 19, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 12, 2021	EX-3.2	(incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K dated Exhibit 3.2 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF February 11, 2021 ARTICLE I OFFICES Section 1. AGENT FOR THE SERVICE OF PROCESS. The agent for the service of process in the State of Maryland shall be CSC Lawyers Incorporating Service Company, 7th St. Paul St., Suite 820, Baltimore, MD 21202. Section 2. OTHER OFFICES. The Corporation may have offices at such other places withi
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 19)* Bal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 19)* Balchem Corporation (Name of Issuer) Common Stock, $.06 2/3 Par Value (Title of Class of Securities) 057665200 (CUSIP Number) Eddie C. Brown Brown Capita
February 12, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 10, 2021 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Balchem Corp. Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule
December 30, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 28, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
December 17, 2020	EX-99.1	Balchem Corporation Announces Dividend Exhibit 99.1 FOR IMMEDIATE RELEASE Balchem Corporation Announces Dividend New Hampton, New York. December 17, 2020. Balchem Corporation (NASDAQ: BCPC) today announced that on December 16, 2020, its Board of Directors declared a dividend on its shares of common stock equal to $0.58 per share on the Company’s issued and outstanding Common Stock, to be payable on January 22, 2021 to stockholders of r
December 17, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 16, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
October 28, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 28, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
October 28, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
October 28, 2020	EX-99.1	Balchem Corporation Reports Record Third Quarter Sales of $175.1 Million, Net Earnings of $21.6 Million, GAAP EPS of $0.66, and Adjusted EPS of $0.83 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record Third Quarter Sales of $175.1 Million, Net Earnings of $21.6 Million, GAAP EPS of $0.66, and Adjusted EPS of $0.83 New Hampton, NY, October 28, 2020 - Balchem Corporation (NASDAQ: BCPC) reported today record third quarter net earnings of $21.6 million for 2020, compared to net
October 16, 2020	8-K	- 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 13, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
August 10, 2020	SC 13G/A	BCPC / Balchem Corp. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 18)* Balchem Corporation (Name of Issuer) Common Stock, $.06 2/3 Par Value (Title of Class of Securities) 057665200 (CUSIP Number) Eddie C. Brown Brown Capita
July 31, 2020	EX-99.1	Balchem Corporation Reports Record Second Quarter Sales of $173.4 Million, Net Earnings of $21.1 Million, GAAP EPS of $0.65, and Adjusted EPS of $0.85 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports Record Second Quarter Sales of $173.4 Million, Net Earnings of $21.1 Million, GAAP EPS of $0.65, and Adjusted EPS of $0.85 New Hampton, NY, July 31, 2020 - Balchem Corporation (NASDAQ: BCPC) reported today record second quarter net earnings of $21.1 million for 2020, compared to net e
July 31, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Corp
July 31, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 31, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 23, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 18, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 001-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
June 23, 2020	EX-3.2	By-laws of the Company, as amended and restated as of June 18, 2020 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K dated June 23, 2020) Exhibit 3.2 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF JUNE 18, 2020 ARTICLE I OFFICES Section 1. AGENT FOR THE SERVICE OF PROCESS. The agent for the service of process in the State of Maryland shall be CSC Lawyers Incorporating Service Company, 7th St. Paul St., Suite 820, Baltimore, MD 21202. Section 2. OTHER OFFICES. The Corporation may have offices at such other places within or
June 12, 2020	11-K	- FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the addre
May 1, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Cor
May 1, 2020	EX-99.1	Balchem Corporation Reports First Quarter Sales of $174.4 Million, GAAP EPS of $0.61 and Adjusted EPS of $0.81 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health \| Specialty Products Balchem Corporation Reports First Quarter Sales of $174.4 Million, GAAP EPS of $0.61 and Adjusted EPS of $0.81 New Hampton, NY, May 1, 2020 - Balchem Corporation (NASDAQ: BCPC) reported today for the first quarter 2020 net earnings of $19.8 million, compared to net earnings of $18.8 million for the first quarter
May 1, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 1, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Numb
April 27, 2020	DEF 14A	- DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
April 27, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
February 21, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 21, 2020 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 21, 2020	EX-21	Subsidiaries of Registrant. Exhibit 21 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization BCP Ingredients, Inc.
February 21, 2020	EX-99.1	Balchem Corporation Reports Record Fourth Quarter Sales of $166.5 Million, GAAP EPS of $0.63 and Adjusted EPS of $0.88 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health Specialty Products \| Industrial Products Balchem Corporation Reports Record Fourth Quarter Sales of $166.5 Million, GAAP EPS of $0.63 and Adjusted EPS of $0.88 New Hampton, NY, February 21, 2020 - Balchem Corporation (NASDAQ: BCPC) today reported for the fourth quarter 2019 net earnings of $20.4 million, compared to net earnings of
February 21, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
February 14, 2020	SC 13G/A	BCPC / Balchem Corp. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 17)* Balchem Corporation (Name of Issuer) Common Stock, $.06 2/3 Par Value (Title of Class of Securities) 057665200 (CUSIP Number) Eddie C. Brown Brown Capita
February 12, 2020	SC 13G/A	BCPC / Balchem Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Balchem Corp Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1
December 19, 2019	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 17, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
December 19, 2019	EX-99.1	Balchem Corporation Announces Dividend Exhibit 99.1 FOR IMMEDIATE RELEASE Balchem Corporation Announces Dividend New Hampton, New York. December 18, 2019. Balchem Corporation (NASDAQ: BCPC) today announced that on December 17, 2019, its Board of Directors declared a dividend on its shares of common stock equal to $0.52 per share, payable on January 17, 2020 to holders of record on December 30, 2019. This dividend reflects a 10.6% incre
December 19, 2019	EX-3.2	By-laws of the Company, as amended and restated as of December 17, 2019 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K dated December 19, 2019 Exhibit 3.2 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF DECEMBER 17, 2019 ARTICLE I OFFICES Section 1. AGENT FOR THE SERVICE OF PROCESS. The agent for the service of process in the State of Maryland shall be CSC Lawyers Incorporating Service Company, 7th St. Paul St., Suite 820, Baltimore, MD 21202. Section 2. OTHER OFFICES. The corporation may have offices at such other places withi
December 18, 2019	EX-99.1	Balchem Corporation Acquires Zumbro River Brand, Inc. Exhibit 99.1 Balchem Corporation Acquires Zumbro River Brand, Inc. New Hampton, New York, December 16, 2019. Balchem Corporation (NASDAQ: BCPC) today announced the acquisition of Zumbro River Brand, Inc. (“Zumbro”), headquartered in Albert Lea, MN. Zumbro specializes in developing, marketing, and manufacturing agglomerated and extruded products for the food and beverage industry and is a market le
December 18, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 13, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 001-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission F
December 18, 2019	EX-2.1	Equity Purchase Agreement relating to the Equity Interests of Zumbro River Brand, Inc. and Prairie Resources, LLC dated as of December 13, 2019 (incorporated by reference to the Company’s Current Report on Form 8-K Dated December 18, 2019) (certain exhibits and schedules to the Equity Purchase Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K and the Company will furnish a copy of any such omitted exhibit or Schedule to the SEC upon Request)). Exhibit 2.1 EXECUTION VERSION EQUITY PURCHASE AGREEMENT RELATING TO THE EQUITY INTERESTS OF ZUMBRO RIVER BRAND, INC. AND PRAIRIE RESOURCES, LLC dated as of December 13, 2019 SCHEDULES AND EXHIBITS iv ARTICLE I Purchase and Sale 1 Section 1.01 Purchase and Sale 1 Section 1.02 Purchase Price 1 Section 1.03 Closing Payments 2 Section 1.04 Determination of Estimated Purchase Price 3 Section 1.05 Deter
November 5, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 5, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
November 5, 2019	EX-99.1	Balchem Corporation Reports Third Quarter Sales of $158.6 Million, GAAP EPS of $0.64 and Adjusted EPS of $0.81 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health Specialty Products \| Industrial Products Balchem Corporation Reports Third Quarter Sales of $158.6 Million, GAAP EPS of $0.64 and Adjusted EPS of $0.81 New Hampton, NY, November 5, 2019 - Balchem Corporation (NASDAQ: BCPC) today reported for the third quarter 2019 net earnings of $20.7 million, compared to net earnings of $19.2 mill
November 5, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem C
November 5, 2019	EX-3.2	Balchem Corporation By-Laws as Amended and Restated as of September 12, 2019. Exhibit 3.2 BALCHEM CORPORATION BY-LAWS AS AMENDED AND RESTATED AS OF SEPTEMBER 12, 2019 ARTICLE I OFFICES Section 1. AGENT FOR THE SERVICE OF PROCESS. The agent for the service of process in the State of Maryland shall be CSC Lawyers Incorporating Service Company, 7th St. Paul St., Suite 820, Baltimore, MD 21202. Section 2. OTHER OFFICES. The corporation may have offices at such other places with
September 12, 2019	EX-3.2	Article III, Section 2 of the Bylaws is hereby deleted and replaced with the following: Exhibit 3.2 – Bylaws Amendments – Effective September 12, 2019. 1. Article III, Section 2 of the Bylaws is hereby deleted and replaced with the following: “Article III, Section 2. NUMBER, CLASSIFICATION AND TENURE. The number of directors of the Corporation shall be eight (8). The Board of Directors are divided into three classes, Class 1, Class 2, and Class 3, who have staggered three-year terms.
September 12, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 12, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 001-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission
August 2, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 2, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 001-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
August 1, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 1, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File N
August 1, 2019	EX-99.1	Balchem Corporation Reports Second Quarter Sales of $161.6 Million, GAAP EPS of $0.61 and Adjusted EPS of $0.77 Exhibit 99.1 Human Nutrition & Health \| Animal Nutrition & Health Specialty Products \| Industrial Products Balchem Corporation Reports Second Quarter Sales of $161.6 Million, GAAP EPS of $0.61 and Adjusted EPS of $0.77 New Hampton, NY, August 1, 2019 - Balchem Corporation (NASDAQ: BCPC) today reported for the second quarter 2019 net earnings of $19.8 million, compared to net earnings of $19.7 mill
August 1, 2019	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Corpor
June 21, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 20, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
June 18, 2019	11-K	BCPC / Balchem Corp. 11-K - - FORM 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the addre
May 28, 2019	EX-99.1	Balchem Corporation Completes Acquisition of Chemogas Exhibit 99.1 Balchem Corporation Completes Acquisition of Chemogas New Hampton, New York. May 28, 2019. Balchem Corporation (NASDAQ:BCPC) today announced that it completed its acquisition of Chemogas, NV, a privately held specialty gases company, headquartered in Grimbergen, Belgium. The signing of a definitive agreement to acquire Chemogas, NV was previously announced on May 2, 2019. With this ac
May 28, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 27, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Num
May 6, 2019	EX-99.1	Balchem Corporation Signs Definitive Agreement to Acquire Chemogas NV Exhibit 99.1 Balchem Corporation Signs Definitive Agreement to Acquire Chemogas NV New Hampton, New York, May 2, 2019. Balchem Corporation (NASDAQ: BCPC) today announced that it has signed a definitive agreement to acquire Chemogas NV, a privately held specialty gases company, headquartered in Grimbergen, Belgium, from Benelux private equity firm Gilde Equity Management and Chemogas management. Th
May 6, 2019	EX-2.1	Securities Purchase Agreement among (a) Balchem, (b) Chemogas Gilde B.V., a limited liability company organized and existing under the laws of The Netherlands, (c) Dirk Battig, (d) Dirk Van den Borre, (e) Eric Matthijs, (f) Christophe Marque, (g) Adamo Pia (h) Jurgen De Smet, and (i) Sebastien Verwilghen, dated as of May 2, 2019 (incorporated by reference to the Company’s Current Report on Form 8-K dated May 6, 2019) (certain exhibits and schedules to the Securities Purchase Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K and the Company will furnish a copy of any such omitted exhibit or Schedule to the SEC upon Request)). Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (A) NOT MATERIAL AND (B) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED Securities Purchase Agreement Between: (1) Chemgas Gilde B.V., a limited liability company organized and existing under the laws of The Netherlands, having its registered office at Heemsteedseweg 22, NL-3992 LS Houten (The N
May 6, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 2, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Numb
May 3, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 3, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Numb
May 3, 2019	EX-99.1	Balchem Corporation Reports First Quarter Sales of $157.0 Million, First Quarter GAAP EPS of $0.58 and Adjusted EPS of $0.73 Exhibit 99.1 Human Nutrition & Health Animal Nutrition & Health Specialty Products Industrial Products Balchem Corporation Reports First Quarter Sales of $157.0 Million, First Quarter GAAP EPS of $0.58 and Adjusted EPS of $0.73 New Hampton, NY, May 3, 2019 - Balchem Corporation (NASDAQ: BCPC) today reported for the first quarter 2019 net earnings of $18.8 million, compared to net earnings of $19.3
May 3, 2019	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem Cor
April 29, 2019	DEFA14A	BCPC / Balchem Corp. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 29, 2019	DEF 14A	BCPC / Balchem Corp. DEF 14A DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14
February 28, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 28, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 28, 2019	EX-99.1	Balchem Corporation Reports Strong Finish to 2018 with Fourth Quarter Sales of $163.5 million, Fourth Quarter GAAP EPS of $0.63 and Adjusted EPS of $0.77 Exhibit 99.1 Human Nutrition & Health Animal Nutrition & Health Specialty Products Industrial Products Balchem Corporation Reports Strong Finish to 2018 with Fourth Quarter Sales of $163.5 million, Fourth Quarter GAAP EPS of $0.63 and Adjusted EPS of $0.77 • Fourth quarter net sales of $163.5 million, growth of 2.7%, compared to prior year. Full year 2018 sales of $643.7 million, an increase of 8.
February 28, 2019	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13648 Balchem
February 28, 2019	EX-21	Subsidiaries of Registrant. Exhibit 21 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization BCP Ingredients, Inc. Delaware Balchem BV Netherlands Balchem Italia Srl Italy Bioscreen Technologies Srl Italy Balchem Ltd. Canada Aberco, Inc. Maryland SensoryEffects, Inc. Delaware SensoryEffects Cereal Systems, Inc. Delaware Albion Laboratories, Inc. Nevada Innovative Food Processors, Inc. Delaware
February 28, 2019	EX-10.10	Forms of Restricted Stock Grant Agreement, Performance Share Unit Grant Agreement and Stock Option Agreement under the Balchem Corporation 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.10 to the Company's Annual Report on Form 10-K for the year ended December 31, 2018). Exhibit 10.10 FINAL FORMS OF AGREEMENT BALCHEM CORPORATION EMPLOYEES RESTRICTED STOCK GRANT AGREEMENT 2017 Omnibus Incentive Plan RESTRICTED STOCK GRANT AGREEMENT made as of this th day of , , between Balchem Corporation, Inc., a Maryland corporation (the “Company”) and (“Grantee”). 1. Grant of Restricted Stock. Pursuant to the Company’s 2017 Omnibus Incentive Plan (the “Plan”), the Company hereby
February 14, 2019	SC 13G/A	BCPC / Balchem Corp. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 16)* Balchem Corporation (Name of Issuer) Common Stock, $.06 2/3 Par Value (Title of Class of Securities) 057665200 (CUSIP Number) Eddie C. Brown Brown Capita
February 11, 2019	SC 13G/A	BCPC / Balchem Corp. / VANGUARD GROUP INC Passive Investment balchemcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8 )* Name of issuer: Balchem Corp Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designat
February 4, 2019	EX-99.1	EXHIBIT 99.1 EXHIBIT 99.1 NEW HAMPTON, NY – February 4, 2019 – Balchem Corporation (NASDAQ: BCPC) announced today the appointment of Martin Bengtsson as Chief Financial Officer (CFO), effective immediately. Mr. Bengtsson will report directly to Theodore L. Harris, President, Chief Executive Officer, and Chairman. Mr. Bengtsson joins Balchem following a successful 15-year career at Honeywell, Inc. Martin progre
February 4, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 4, 2019 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
February 4, 2019	EX-10.1	Offer Letter, dated as of January 10, 2019, between the Company and Martin Bengtsson (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated February 4, 2019). EXHIBIT 10.1 January 10, 2019 Martin Bengtsson 9 Barnsdale Road Madison, NJ Dear Martin: I am pleased to make the following offer to you for the position of Chief Financial Officer with Balchem Corporation (“Balchem” or the “Company”) a compensation package as described below: Annual base salary: $ 435,000 Date of Hire: February 4, 2019 · Incentive Compensation: You will also be eligible to partic
December 13, 2018	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 13, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-257-8432 (State or other jurisdiction of incorporation) (Commission Fi
December 13, 2018	EX-99.1	Balchem Corporation Announces Dividend Exhibit 99.1 FOR IMMEDIATE RELEASE Balchem Corporation Announces Dividend New Hampton, New York. December 13, 2018. Balchem Corporation (NASDAQ: BCPC) today announced that on December 12, 2018, its Board of Directors declared a dividend on its shares of common stock equal to $0.47 per share, payable on January 18, 2019 to holders of record on December 26, 2018. This dividend reflects an 11.9% incr
November 6, 2018	EX-99.1	Balchem Corporation Reports Quarterly Sales of $155.0 Million, Record Third Quarter Net Earnings of $19.2 Million, Record Third Quarter Adjusted Net Earnings of $23.7 Million, and Record Third Quarter Adjusted EBITDA of $38.4 Million Exhibit 99.1 Balchem Corporation Reports Quarterly Sales of $155.0 Million, Record Third Quarter Net Earnings of $19.2 Million, Record Third Quarter Adjusted Net Earnings of $23.7 Million, and Record Third Quarter Adjusted EBITDA of $38.4 Million New Hampton, NY, November 6, 2018 – Balchem Corporation (NASDAQ: BCPC) today reported for the third quarter 2018 record third quarter net earnings of $19
November 6, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 6, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File
November 6, 2018	10-Q	Quarterly Report - 10-Q FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For The Quarterly Period Ended September 30, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 1-13648 BALCHEM CORPORATION (E
October 19, 2018	CORRESP	BCPC / Balchem Corp. CORRESP October 19, 2018 BY EDGAR Ms. Jeanne Baker, Assistant Chief Accountant United States Securities and Exchange Commission Division of Corporation Finance – Office of Manufacturing and Construction Washington, D.C. 20549 Re: Balchem Corporation Form 10-Q for Fiscal Quarter Ended June 30, 2018 Filed August 3, 2018 Form 10-K for Fiscal Year Ended December 31, 2017 Filed March 1, 2018 File No. 001-13648
September 28, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 26, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fi
September 28, 2018	EX-10.1	SEPARATION AGREEMENT AND GENERAL RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) is entered into by and between Balchem Corporation, at 52 Sunrise Park Road, New Hampton, New York 10958, (“Employer”) and Mary Theresa Coelho, 8904 Woodhall Lake Dr., Waxhaw, North Carolina 28173, her heirs, executors, administrators, successors, and assigns (collectively, the “Em
September 10, 2018	SC 13G/A	BCPC / Balchem Corp. / VANGUARD GROUP INC Passive Investment balchemcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7 )* Name of issuer: Balchem Corp Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: August 31, 2018 Check the appropriate box to designate
August 3, 2018	EX-99.1	Balchem Corporation Reports Record Quarterly Sales of $163.7 Million, Record Second Quarter Net Earnings of $19.7 Million, Record Adjusted Net Earnings of $24.5 Million and Record Adjusted EBITDA of $41.0 Million Exhibit 99.1 Balchem Corporation Reports Record Quarterly Sales of $163.7 Million, Record Second Quarter Net Earnings of $19.7 Million, Record Adjusted Net Earnings of $24.5 Million and Record Adjusted EBITDA of $41.0 Million New Hampton, NY, August 3, 2018 – Balchem Corporation (NASDAQ: BCPC) today reported for the second quarter 2018 record second quarter net earnings of $19.7 million, compared
August 3, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 3, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File N
August 3, 2018	10-Q	BCPC / Balchem Corp. 10-Q (Quarterly Report) FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For The Quarterly Period Ended June 30, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 1-13648 BALCHEM CORPORATION (Exact
July 5, 2018	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-257-8432 (State or other jurisdiction of incorporation) (Commission File N
July 5, 2018	EX-4.2	Security and Pledge Agreement dated June 27, 2018 among Balchem Corporation, the Domestic Guarantors and JPMorgan Chase Bank, N.A., (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K dated July 5, 2018). Exhibit 4.2 EXECUTION COPY SECURITY AND PLEDGE AGREEMENT THIS SECURITY AND PLEDGE AGREEMENT (this “Agreement”) is entered into as of June 27, 2018 among BALCHEM CORPORATION, a Maryland corporation (the “Parent”), the other parties identified as “Obligors” on the signature pages hereto and such other parties that may become Obligors hereunder after the date hereof (each individually an “Obligor” an
July 5, 2018	EX-4.1	Credit Agreement dated June 27,2018 among Balchem Corporation, the Domestic Guarantors (as defined in the Credit Agreement), JPMorgan Chase Bank, N.A., as administrative agent, and the Lenders guarantors (as defined in the Credit Agreement) (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K dated July 5, 2018). Exhibit 4.1 EXECUTION COPY CREDIT AGREEMENT Dated as of June 27, 2018 among BALCHEM CORPORATION, as the Parent, THE FOREIGN SUBSIDIARIES OF THE PARENT IDENTIFIED HEREIN, as the Foreign Borrowers, THE SUBSIDIARIES OF THE PARENT IDENTIFIED HEREIN, as the Guarantors, JPMORGAN CHASE BANK, N.A., as Administrative Agent, BANK OF AMERICA, N.A. and FARM CREDIT SERVICES OF AMERICA, PCA, as Syndication Agen
July 5, 2018	EX-99.1	Balchem Completes Debt Refinancing with Five Year Senior Secured Credit Facility Exhibit 99.1 Balchem Completes Debt Refinancing with Five Year Senior Secured Credit Facility New Hampton, NY, June 27, 2018. Balchem Corporation (NASDAQ: BCPC) announced that the Company has entered into a new credit agreement with its lenders in the form of a senior secured revolving credit facility, due 2023. The new revolving credit agreement allows for up to $500 million of borrowing. The Com
June 22, 2018	11-K	BCPC / Balchem Corp. 11-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-13648 A. Full title of the plan and the address o
June 21, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 20, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Nu
May 4, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 4, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission File Numb
May 4, 2018	EX-99.1	Balchem Corporation Reports Record First Quarter Sales of $161.4 Million, Record First Quarter Net Earnings of $19.3 Million, Record Adjusted Net Earnings of $24.4 Million and Record Adjusted EBITDA of $40.9 Million Exhibit 99.1 Balchem Corporation Reports Record First Quarter Sales of $161.4 Million, Record First Quarter Net Earnings of $19.3 Million, Record Adjusted Net Earnings of $24.4 Million and Record Adjusted EBITDA of $40.9 Million New Hampton, NY, May 4, 2018 – Balchem Corporation (NASDAQ: BCPC) today reported for the first quarter 2018 record first quarter net earnings of $19.3 million, compared to
May 4, 2018	10-Q	BCPC / Balchem Corp. 10-Q (Quarterly Report) FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For The Quarterly Period Ended March 31, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 1-13648 BALCHEM CORPORATION (Exact
April 30, 2018	DEFA14A	BCPC / Balchem Corp. DEFA 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 30, 2018	DEF 14A	BCPC / Balchem Corp. DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 1, 2018	EX-21	LIST OF SUBSIDIARIES Exhibit 21 LIST OF SUBSIDIARIES Subsidiaries of the Registrant Jurisdiction of Organization BCP Ingredients, Inc. Delaware Balchem BV Netherlands Balchem Italia Srl Italy Balchem Ltd. Canada Aberco, Inc. Maryland SensoryEffects, Inc. Delaware SensoryEffects Cereal Systems, Inc. Delaware Albion Laboratories, Inc. Nevada Innovative Food Processors, Inc. Delaware
March 1, 2018	10-K	BCPC / Balchem Corp. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 1-13648 Balche
February 28, 2018	EX-99.1	Balchem Corporation Reports Fourth Quarter Sales of $159.3 Million with Record Net Earnings of $42.0 Million, Record Adjusted Net Earnings of $21.9 Million and Record Adjusted EBITDA of $40.0 Million Exhibit 99.1 Balchem Corporation Reports Fourth Quarter Sales of $159.3 Million with Record Net Earnings of $42.0 Million, Record Adjusted Net Earnings of $21.9 Million and Record Adjusted EBITDA of $40.0 Million New Hampton, NY, February 27, 2018 ? Balchem Corporation (NASDAQ: BCPC) today reported for the fourth quarter 2017 record quarterly net earnings of $42.0 million, compared to net earnings
February 28, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 27, 2018 Balchem Corporation (Exact name of registrant as specified in its charter) Maryland 1-13648 13-2578432 (State or other jurisdiction of incorporation) (Commission Fil
February 15, 2018	SC 13G/A	BCPC / Balchem Corp. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* BALCHEM CORP (Name of Issuer) Common (Title of Class of Securities) 057665200 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
February 14, 2018	SC 13G/A	BCPC / Balchem Corp. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 15)* Balchem Corporation (Name of Issuer) Common Stock, $.06 2/3 Par Value (Title of Class of Securities) 057665200 (CUSIP Number) December 31, 2017 (Date of
February 12, 2018	SC 13G/A	BCPC / Balchem Corp. / VANGUARD GROUP INC Passive Investment balchemcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6 )* Name of issuer: Balchem Corp Title of Class of Securities: Common Stock CUSIP Number: 057665200 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designat

BCPC / Balchem Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings